Presentation is loading. Please wait.

Presentation is loading. Please wait.

Highlights of the Day-Plenary Session June 1, 2014 Lowell E. Schnipper, M.D. Presented By Lowell Schnipper at 2014 ASCO Annual Meeting.

Published bySamson Nicholson Modified over 9 years ago

Similar presentations

Presentation on theme: "Highlights of the Day-Plenary Session June 1, 2014 Lowell E. Schnipper, M.D. Presented By Lowell Schnipper at 2014 ASCO Annual Meeting."— Presentation transcript:

1 Highlights of the Day-Plenary Session June 1, 2014 Lowell E. Schnipper, M.D. Presented By Lowell Schnipper at 2014 ASCO Annual Meeting

2 Why invite a value discussion? Presented By Lowell Schnipper at 2014 ASCO Annual Meeting

3 Clinically Meaningful Outcomes and Implications for Value (Ellis, et al.,J Clin Oncol. 2014 Apr 20;32(12):1277-80 Presented By Lowell Schnipper at 2014 ASCO Annual Meeting

4 Moving the Discussion to Value it’s far more than Cost Presented By Lowell Schnipper at 2014 ASCO Annual Meeting

5 Seeking an Association Between Clinical Benefit, Toxicity and Cost Presented By Lowell Schnipper at 2014 ASCO Annual Meeting

6 Phase III ALTTO trial The ALTTO trial did not meet its endpoints (DFS): Neither the L + T vs. T comparison nor the T → L vs. T comparison Presented By Lowell Schnipper at 2014 ASCO Annual Meeting

7 Randomized comparison of adjuvant aromatase inhibitor (AI) exemestane (E) plus ovarian function suppression (OFS) vs tamoxifen (T) plus OFS in premenopausal women with hormone receptor-positive (HR+) early breast cancer (BC): Joint analysis of IBCSG TEXT and SOFT trials. Presented By Lowell Schnipper at 2014 ASCO Annual Meeting

8 E3805 CHAARTED: ChemoHormonal Therapy versus Androgen Ablation Randomized Trial for Extensive Disease in Prostate Cancer Presented By Lowell Schnipper at 2014 ASCO Annual Meeting

Download ppt "Highlights of the Day-Plenary Session June 1, 2014 Lowell E. Schnipper, M.D. Presented By Lowell Schnipper at 2014 ASCO Annual Meeting."

Similar presentations

Presented By Martine Piccart-Gebhart at 2014 ASCO Annual Meeting

Presented By Martine Piccart-Gebhart at 2014 ASCO Annual Meeting
First Efficacy Results of a Randomized, Open- Label, Phase III Study of Adjuvant Doxorubicin Plus Cyclophosphamide, Followed by Docetaxel with or without.

First Efficacy Results of a Randomized, Open- Label, Phase III Study of Adjuvant Doxorubicin Plus Cyclophosphamide, Followed by Docetaxel with or without.
Xeloda X-panding options in the adjuvant treatment of breast cancer

Xeloda X-panding options in the adjuvant treatment of breast cancer
ASCO G.U. 2014 Lawrence H. Einhorn.

ASCO G.U Lawrence H. Einhorn.
Intraperitoneal therapy in ovarian cancer Edward L. Trimble, MD, MPH National Cancer Institute, USA.

Intraperitoneal therapy in ovarian cancer Edward L. Trimble, MD, MPH National Cancer Institute, USA.
Obesity at Diagnosis Is Associated with Inferior Outcomes in Hormone Receptor Positive Breast Cancer 1 The Impact of Body Mass Index (BMI) on the Efficacy.

Obesity at Diagnosis Is Associated with Inferior Outcomes in Hormone Receptor Positive Breast Cancer 1 The Impact of Body Mass Index (BMI) on the Efficacy.
Slide 1 Presented By Mark Stein at 2014 ASCO Annual Meeting.

Slide 1 Presented By Mark Stein at 2014 ASCO Annual Meeting.
Choosing between different hormonal therapies Rudy Van den Broecke UZ Ghent.

Choosing between different hormonal therapies Rudy Van den Broecke UZ Ghent.
American Society of Clinical Oncology Endorsement of the Cancer Care Ontario (CCO) Practice Guideline on Adjuvant Ovarian Ablation (OA) in the Treatment.

American Society of Clinical Oncology Endorsement of the Cancer Care Ontario (CCO) Practice Guideline on Adjuvant Ovarian Ablation (OA) in the Treatment.
The 70-Gene Profile and Chemotherapy Benefit in 1,600 Breast Cancer Patients Bender RA et al. ASCO 2009; Abstract 512. (Oral Presentation)

The 70-Gene Profile and Chemotherapy Benefit in 1,600 Breast Cancer Patients Bender RA et al. ASCO 2009; Abstract 512. (Oral Presentation)
CONTROVERSIES IN ADJUVANT ENDOCRINE THERAPY AROMATASE INHIBITORS

CONTROVERSIES IN ADJUVANT ENDOCRINE THERAPY AROMATASE INHIBITORS
Everolimus in Postmenopausal Hormone-Receptor–Positive Advanced Breast Cancer N Engl J Med 2011 Dec 7. Presenstor : CR 周益聖 Instructor : VS 趙大中 財團法人台灣癌症臨床研究發展基金會.

Everolimus in Postmenopausal Hormone-Receptor–Positive Advanced Breast Cancer N Engl J Med 2011 Dec 7. Presenstor : CR 周益聖 Instructor : VS 趙大中 財團法人台灣癌症臨床研究發展基金會.
Clinical Relevance of HER2 Overexpression/Amplification in Patients with Small Tumor Size and Node-Negative Breast Cancer Curigliano G et al. J Clin Oncol.

Clinical Relevance of HER2 Overexpression/Amplification in Patients with Small Tumor Size and Node-Negative Breast Cancer Curigliano G et al. J Clin Oncol.
Department of Surgery, United Christian Hospital Aromatase Inhibitors Current Use in Breast Cancer JHGR 16 Jan 2005 Dr. Sharon Chan Department of Surgery,

Department of Surgery, United Christian Hospital Aromatase Inhibitors Current Use in Breast Cancer JHGR 16 Jan 2005 Dr. Sharon Chan Department of Surgery,
Prevention of Early Menopause Study (POEMS)-S0230 Phase III trial of LHRH analog during chemotherapy to reduce ovarian failure in early stage, hormone.

Prevention of Early Menopause Study (POEMS)-S0230 Phase III trial of LHRH analog during chemotherapy to reduce ovarian failure in early stage, hormone.
Hormonally Sensitive Early-Stage Breast Cancer Current Considerations and New Directions Terry Mamounas, MD, MPH Professor of Surgery Northeastern Ohio.

Hormonally Sensitive Early-Stage Breast Cancer Current Considerations and New Directions Terry Mamounas, MD, MPH Professor of Surgery Northeastern Ohio.
Significantly Higher Pathologic Complete Remission Rate After Neoadjuvant Therapy with Trastuzumab, Paclitaxel, and Epirubicin Chemotherapy: Results of.

Significantly Higher Pathologic Complete Remission Rate After Neoadjuvant Therapy with Trastuzumab, Paclitaxel, and Epirubicin Chemotherapy: Results of.
Breast Plenary Abstracts How Do These Studies Impact Clinical Practice Today and in the Years Ahead? Presented By Eric Winer at 2014 ASCO Annual Meeting.

Breast Plenary Abstracts How Do These Studies Impact Clinical Practice Today and in the Years Ahead? Presented By Eric Winer at 2014 ASCO Annual Meeting.
The Effect of Zoledronic Acid (ZOL) on Aromatase Inhibitor-Associated Bone Loss in Postmenopausal Women with Early Breast Cancer Receiving Adjuvant Letrozole:

The Effect of Zoledronic Acid (ZOL) on Aromatase Inhibitor-Associated Bone Loss in Postmenopausal Women with Early Breast Cancer Receiving Adjuvant Letrozole:
Long-Term Effects of Continuing Adjuvant Tamoxifen to 10 Years versus Stopping at 5 Years After Diagnosis of Oestrogen Receptor- Positive Breast Cancer:

Long-Term Effects of Continuing Adjuvant Tamoxifen to 10 Years versus Stopping at 5 Years After Diagnosis of Oestrogen Receptor- Positive Breast Cancer:

Similar presentations

Ads by Google